We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Janux Therapeutics has raised $125m through a series B funding round to advance its pipeline of next-generation T cell engager immunotherapies into initial proof of concept (PoC) clinical trials.